Comparative Pharmacology
Head-to-head clinical analysis: AQUATENSEN versus ZESTORETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUATENSEN versus ZESTORETIC.
AQUATENSEN vs ZESTORETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AQUATENSEN (methylclothiazide) is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule of the nephron, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and blood pressure.
Combination of lisinopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic). Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, increasing diuresis and reducing plasma volume.
1-2 mg orally once daily, titrated to blood pressure response; maximum dose 4 mg/day.
Zestoretic (lisinopril/hydrochlorothiazide) is available in fixed-dose combinations. Typical adult dose: 10 mg/12.5 mg, 20 mg/12.5 mg, or 20 mg/25 mg orally once daily. Maximum dose: lisinopril 80 mg/day, hydrochlorothiazide 50 mg/day.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours (mean 10 h); clinically, allows twice-daily dosing
Lisinopril: terminal half-life approximately 12 hours (accumulation half-life 13.8 hours in patients with normal renal function). Hydrochlorothiazide: terminal half-life 5.6–14.8 hours (mean 9.6 hours).
Renal: 50% unchanged; Fecal: 20% (via bile); remainder as inactive metabolites
Lisinopril is excreted unchanged in urine; 100% renal elimination. Hydrochlorothiazide is excreted primarily by the kidney (≥95% as unchanged drug) via tubular secretion.
Category C
Category C
Diuretic
ACE Inhibitor + Diuretic